Alameda, CA – According to filings with the U.S. Securities and Exchange Commission, Mimosa Therapeutics is raising $1,675,936.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James Keims played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Mimosa Therapeutics

MIMOSA is drastically changing the market by offering all-natural psilocybin, grown as mycelia (“roots” of mushrooms) in scalable “brewers.” Mimosa’s psilocybin brewers can range in size from 2 gallon microbrewers to 50,000 gallon brew vats. The process can be 100% organic (OMRI – Organic Materials Review Institute) compliant, requiring no genetic modifications, no synthetic chemistry and no solvents of any kind. This creates consistent full-spectrum psilocybin, with options for pure psilocybin as well as for measured combinations with baeocystin and other complementary molecules, that is cleaner, less expensive, and superior in quality to traditionally offered entheogenic mushrooms or truffles.

To learn more about Mimosa Therapeutics, visit http://www.mimosatherapeutics.com/

Contact:
James Keims, Chief Executive Officer
510-693-3914
https://www.linkedin.com/in/james-keim-7a98/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved